Old Drugs for an Old Pathology? Drug Repurposing for Calcific Aortic Valve Disease.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

4 citing papers in PubMed.

1. The Pathogenic Roles of Local Vitamin D Metabolism Defect in Valve Inflammation and Calcification.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025
   Article
2. Immunotherapy in the Context of Aortic Valve Diseases.Cardiovascular drugs and therapy · 2024
   Review
3. Uncoupling the Vicious Cycle of Mechanical Stress and Inflammation in Calcific Aortic Valve Disease.Frontiers in cardiovascular medicine · 2022
   Review
4. Innate and adaptive immunity: the understudied driving force of heart valve disease.Cardiovascular research · 2021
   Review

Corrections and comments

• Comment on
  KPT-330 Prevents Aortic Valve Calcification via a Novel C/EBPβ Signaling Pathway.2021

Authors and funding

2 authors.

Funding

Abstract

PubMed holds no abstract for this paper.

Indexed as